Krystal Biotech Inc (KRYS)

Working capital turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	293,354	247,796	172,511	103,808	58,154	10,946	2,390	809	0	0	0	0	0	0	0	0	0	0	0	542
Total current assets	US$ in thousands	742,045	713,164	682,772	602,248	587,909	582,128	484,004	355,429	383,779	397,578	428,770	437,998	442,267	345,812	369,927	405,826	275,058	287,652	298,539	188,329
Total current liabilities	US$ in thousands	101,995	89,527	71,851	47,589	33,094	27,583	23,898	35,076	28,847	28,032	34,427	60,437	25,736	35,779	18,119	9,144	15,452	7,198	5,831	4,061
Working capital turnover		0.46	0.40	0.28	0.19	0.10	0.02	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

December 31, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $293,354K ÷ ($742,045K – $101,995K)
= 0.46

The working capital turnover ratio for Krystal Biotech Inc has shown a gradual improvement over the years. From 0.01 in June 30, 2023, the ratio increased to 0.46 in December 31, 2024, indicating that the company is able to generate more revenue relative to its working capital.

This improvement suggests that Krystal Biotech Inc has become more efficient in utilizing its working capital to generate sales and is achieving better turnover of its current assets. A higher working capital turnover ratio generally indicates that the company is managing its working capital effectively and is efficient in its operations.

It's important for investors and stakeholders to monitor this ratio as it provides insights into the company's liquidity and operational efficiency.